about
Unconventional genomic architecture in the budding yeast saccharomyces cerevisiae masks the nested antisense gene NAG1.Yapsins are a family of aspartyl proteases required for cell wall integrity in Saccharomyces cerevisiae.Antifungal drug discovery: something old and something newZinc Pyrithione Improves the Antibacterial Activity of Silver Sulfadiazine OintmentCandida albicans mannans mediate Streptococcus mutans exoenzyme GtfB binding to modulate cross-kingdom biofilm development in vivo.Extracellular secretion of overexpressed glycosylphosphatidylinositol-linked cell wall protein Utr2/Crh2p as a novel protein quality control mechanism in Saccharomyces cerevisiae.Efg1 directly regulates ACE2 expression to mediate cross talk between the cAMP/PKA and RAM pathways during Candida albicans morphogenesis.Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase.Candida albicans morphogenesis is not required for macrophage interleukin 1β production.The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Catching fire: Candida albicans, macrophages, and pyroptosis.Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifenA High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis.The RAM network in pathogenic fungi.Complex Haploinsufficiency-Based Genetic Analysis of the NDR/Lats Kinase Cbk1 Provides Insight into Its Multiple Functions in Candida albicans.Live Candida albicans suppresses production of reactive oxygen species in phagocytes.Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterizationCandida albicans triggers NLRP3-mediated pyroptosis in macrophages.Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms in vivo.Antifungal drug development: challenges, unmet clinical needs, and new approaches.Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs.Genetic analysis of the Candida albicans biofilm transcription factor network using simple and complex haploinsufficiency.Challenges in the development of novel anticryptococcal agents.High-Throughput Screen in Cryptococcus neoformans Identifies a Novel Molecular Scaffold That Inhibits Cell Wall Integrity Pathway Signaling.The Candida albicans transcription factor Cas5 couples stress responses, drug resistance and cell cycle regulation.A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis.Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity.Transcription factor network efficiency in the regulation of Candida albicans biofilms: it is a small world.The unmet clinical need of novel antifungal drugs.Age and symptoms affect the prevalence of group A beta-hemolytic streptococcus in pharyngeal cultures of school-age children.Systematic Complex Haploinsufficiency-Based Genetic Analysis of Candida albicans Transcription Factors: Tools and Applications to Virulence-Associated Phenotypes.High-Throughput Screening Identifies Genes Required for Induction of Macrophage PyroptosisRepurposing Estrogen Receptor Antagonists for the Treatment of Infectious DiseaseCandida-streptococcal interactions in biofilm-associated oral diseasesStructural basis for species-selective targeting of Hsp90 in a pathogenic fungus.Synthesis of peptidyl methylcoumarin esters as substrates and active-site titrants for the prohormone processing proteases Kex2 and PC2Quantitative characterization of furin specificity. Energetics of substrate discrimination using an internally consistent set of hexapeptidyl methylcoumarinamidesTreatment with oseltamivir decreases the length of hospital stay in critically ill children with influenza
P50
Q27929800-EEA075E7-4673-4694-B550-8A3CD3FEB48CQ27937998-8962B039-0F56-4EEC-B03C-CF0DBA92D53CQ28483546-ACDD0FC3-A81C-405A-A2C5-A0506BFE9850Q28830227-E58D2783-F539-4131-BD7C-A3FCCD9636A5Q33803358-B39D2B02-1D4F-4C3A-B711-8201BE5A5BC8Q34290571-20C95542-D2DB-4B85-A4B4-3057C011DBDAQ34297595-CF12FBAF-5B4D-4788-99C6-3820CF566F80Q34394167-1D02CAB7-B61F-43EC-B008-3F708883C274Q34522517-6EEFB8E5-5D22-4A0F-ACE6-712EBF25816EQ34523437-99F4CD5F-648B-43B9-8AE2-77D847457D91Q34540684-324422BA-EEE0-49DE-862A-C2EED11EB0DAQ35092521-9E6D90CD-59F7-4CDC-80CB-2E9D67D03457Q35195507-3456BD2F-B5FB-43D4-A369-34C764D52255Q35643319-5B67C484-D944-4D89-B6B4-C6A60C61E7DFQ35670579-594DF062-AC96-4168-82B1-502CC108A390Q36017845-822155A9-FA0D-4B16-9A14-9342C1D49BC6Q36024512-C3986889-D54C-4DD3-AD52-87D7B5379361Q37032994-9E80EEC6-345D-46BA-9413-2C1B928C6BF5Q37274621-573706D6-A8CA-432F-8734-69B5C5474D05Q37545146-DA73EF20-9214-4DF7-84A5-945D0BB3C164Q37713399-A78D71A3-D89E-4CED-88B2-A5AE88829D61Q37717926-3AEB7791-46E4-4878-A4B3-233A63633396Q38290584-5C2D1639-6441-4C38-8D00-418D92BEE400Q38632072-A06CB36B-5882-4367-8886-D34ACDA20C53Q38835037-F120D096-DFFF-4A8D-A85C-1D58F8F9E49CQ40065529-6A4F4AD9-1463-402D-86E6-87072C40832FQ41324079-E044840D-0CDD-4ADF-B225-DDE1369FDEA4Q43030507-A23B2673-BCBE-469A-BA2F-8AF4EA4AE432Q47744179-5E682AEA-2897-475C-BD96-F438FC8C1489Q48274680-E7CFE1C3-E4C2-41CD-8425-96AA76CBB855Q50068450-0463A305-F13F-4DAA-97B7-CEC9B3428594Q51057013-C21BE5DD-D775-4726-B866-C016C410CCBEQ52374553-82ECD348-26E7-4CFA-AB18-DBAD20535C50Q58730105-96040AD6-4177-4221-99AE-550E0B6552C7Q60301184-1E958AB1-AC16-4121-A34A-36924B375450Q60302660-3503D12A-278E-4677-9228-3F9255D6BDABQ61117634-B88C8D9C-42D2-4CAF-BFD6-CBD626FF631CQ73734895-E5C4EA60-06C6-41CE-AAD5-FD9EC45A2FA5Q78101739-13E16677-3CA4-4E64-8C7F-F82DDF550419Q83434642-34843EB3-48B7-42A0-A498-B506ABA56649
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-6330-3365
@en
name
Damian J Krysan
@ast
Damian J Krysan
@en
Damian J Krysan
@es
Damian J Krysan
@nl
type
label
Damian J Krysan
@ast
Damian J Krysan
@en
Damian J Krysan
@es
Damian J Krysan
@nl
prefLabel
Damian J Krysan
@ast
Damian J Krysan
@en
Damian J Krysan
@es
Damian J Krysan
@nl
P106
P1153
6603600279
P31
P496
0000-0001-6330-3365